about
Somatic mutations affect key pathways in lung adenocarcinomaCharacterizing the cancer genome in lung adenocarcinoma.Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipientsInternational Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma.Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer.Resection for esophageal cancer in the elderly.CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cellsOutcomes after esophagectomy in patients with prior antireflux or hiatal hernia surgeryEpigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity.TGM2: a cell surface marker in esophageal adenocarcinomas.Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancerTranscriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyThe multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework.Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis.Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis.Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.The role of Dickkopf-3 overexpression in esophageal adenocarcinomaOsteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma.Management of congenital and acquired pulmonary vein stenosis.Quality indicators for the evaluation of patients with lung cancerIGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.Tension chylothorax.Management of the cervical esophagogastric anastomotic stricture.Two thousand transhiatal esophagectomies: changing trends, lessons learned.Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexityLessons from the national emphysema treatment trial.Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer.Surgical treatment of epiphrenic diverticula: a 30-year experience.Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinomaNonmedical therapy for chronic obstructive pulmonary disease.Barrett's esophagus: genetic and cell changes.Thromboembolic events before esophagectomy for esophageal cancer do not result in worse outcomes.Lung cancer: multidisciplinary approach to tissue sampling.Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Early Oral Feeding Following McKeown Minimally Invasive Esophagectomy: An Open-label, Randomized, Controlled, Noninferiority Trial.
P50
Q24648102-D33E7500-E7CA-4BEC-A516-B77711561E85Q24649926-8964343E-E5CA-480B-87B5-487214DD56C5Q24683927-868A6611-DA16-45A8-B1EC-A28FCAA29676Q30885409-B7BB8865-32D4-4037-B05F-C60477C9A07BQ33281166-347B9BCF-224C-4FBC-8437-0080816AAF0EQ33382046-05A2755D-7E35-4F84-8EBC-7351156B25B4Q33760596-DCCC0747-CF40-4F5B-9E48-6DE7D8A670FFQ33774226-C90C8EC8-354F-4E6E-BE20-7EF260166712Q33792272-639FF95B-8F3C-4D79-B6E3-9478FA1447BCQ33815609-8E1602B8-7A8B-4980-BAC3-D3F97B27408EQ33908966-44436D07-4E6D-4120-A3C6-95FC4840A3B6Q34165233-83F4BB86-9159-4ACC-8E0E-0DC41A2BEC70Q34193882-FA0B0409-350A-48E9-8424-D8FA195FFB1EQ34219975-4FA01275-C713-4DC6-99EE-83CD6AF289F7Q34291420-98B9586A-9DFF-49F7-B810-83AF14C515FBQ34762165-BF658691-88FE-4810-960A-5F546E5FB98AQ34798314-F8B60521-3F33-4E18-9894-4689E9AFD646Q35121180-EA1503A0-A807-4783-80AB-FFACBF85BC70Q35197454-430363F7-E9A6-4213-B8BF-0BC420DDF7E1Q35211240-90831C2C-7C92-477B-816D-6BDC94FB97A6Q35837225-FC8C4F18-AFFA-435F-915D-9A0D2EEBB88AQ35889299-06C9A54D-0AAC-43E5-A6A6-47380236FBF1Q36355935-9F666756-F5A1-432B-8649-7B4EB73C8E02Q36401193-E95E2095-DFEE-4144-96D0-6DA99F7542C4Q36411138-2B5DD041-D5F7-4117-9CB3-905BD265ED4CQ36413323-96979F4B-EDD6-4CF8-9CD4-6B57CC48A9B1Q36545214-698B4352-DC1A-4945-94EA-F66B81AAAFF5Q36778138-A7322A45-A336-42B0-8C78-F281A7D09AAEQ36918601-F1A0E88A-E880-462F-BD1D-C582B39A3715Q36918993-5D5DCCC1-D060-4069-9E1B-1FC6D96E578EQ36942611-32EC2B88-67B4-4E23-A627-65D023411122Q36998286-D29156E5-BDA2-4450-8FB5-0125AD4E8666Q37013491-35077494-E0E3-4098-9115-901221A8AD9BQ37133934-BD90B520-9F41-46A8-BE83-7476DF809FD2Q37365036-DCAF2232-D1EA-469A-827F-2149B18F9CCFQ37939277-BE6A9289-CC3A-4C1E-8BB1-13280C651023Q38031713-65890E60-6DB1-4BD0-870E-C802A9CAF3FAQ38043167-AA57DF9F-048A-4CBA-A2BB-C9FFF1314458Q38104632-108B6BDC-146F-4074-9D90-352C335043E9Q38761456-78234D5D-3388-4DC2-9069-01A9FD73D220
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew C Chang
@nl
Andrew C Chang
@sl
Andrew C. Chang
@en
Andrew C. Chang
@es
type
label
Andrew C Chang
@nl
Andrew C Chang
@sl
Andrew C. Chang
@en
Andrew C. Chang
@es
prefLabel
Andrew C Chang
@nl
Andrew C Chang
@sl
Andrew C. Chang
@en
Andrew C. Chang
@es
P106
P1153
55264333600
P21
P31
P496
0000-0001-9506-0425